Molecular structure of Clarithromycin, CAS Number: 81103-11-9
Clarithromycin (CAS 81103-11-9)
See product citations (1)
Alternate Names:
Biaxin; Cyllind; Klacid
Application:
Clarithromycin is a macrolide antibiotic and protein synthesis inhibitor
CAS Number:
81103-11-9
Purity:
≥98%
Molecular Weight:
747.95
Molecular Formula:
C38H69NO13
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Clarithromycin is a 14-member ring macrolide antibiotic and 6-O-methyl derivative of erythromycin. It has reported bacteriostatic action against gram-positive bacteria and some gram-negative bacteria including anaerobes. Similar to other macrolide antibiotics, this antibiotic is believed to function via binding of the ribosome within the microorganism. Studies have noted that clarithromycin appears to bind specifically to the 50S ribosomal subunit, thus inhibiting DNA translation and inhibiting bacterial growth. This compound is both a substrate and inhibitor of CYP3A4.
Clarithromycin (CAS 81103-11-9) References
- Inhibition of 50S ribosomal subunit assembly in Haemophilus influenzae cells by azithromycin and erythromycin. | Champney, WS. and Miller, M. 2002. Curr Microbiol. 44: 418-24. PMID: 12000992
- Molecular basis of macrolide resistance in Campylobacter: role of efflux pumps and target mutations. | Mamelli, L., et al. 2005. J Antimicrob Chemother. 56: 491-7. PMID: 16055509
- Glycosidase inhibition by macrolide antibiotics elucidated by STD-NMR spectroscopy. | Sadeghi-Khomami, A., et al. 2008. Chem Biol. 15: 739-49. PMID: 18635010
- Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori. | Furuta, T., et al. 2020. Digestion. 101: 743-751. PMID: 31434101
- Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. | Phillips, RO., et al. 2020. Lancet. 395: 1259-1267. PMID: 32171422
- Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study. | Romano, M., et al. 2020. Helicobacter. 25: e12694. PMID: 32314519
- Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. | Hill, K., et al. 2020. JAMA Intern Med. 180: 1052-1060. PMID: 32511684
- Intra-Amniotic Infection with Ureaplasma parvum Causes Preterm Birth and Neonatal Mortality That Are Prevented by Treatment with Clarithromycin. | Motomura, K., et al. 2020. mBio. 11: PMID: 32576673
- Integrative analyses of transcriptomics and metabolomics in Raphidocelis subcapitata treated with clarithromycin. | Peng, J., et al. 2021. Chemosphere. 266: 128933. PMID: 33223212
- Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19? | Gedikli, MA., et al. 2021. Bratisl Lek Listy. 122: 101-110. PMID: 33502877
- The impact and fate of clarithromycin in anaerobic digestion of waste activated sludge for biogas production. | Zeng, S., et al. 2021. Environ Res. 195: 110792. PMID: 33545126
- Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. | Kocsmár, É., et al. 2021. Nat Commun. 12: 2255. PMID: 33859206
- Preparation and Characterization of Controlled-Release Floating Bilayer Tablets of Esomeprazole and Clarithromycin. | Israr, M., et al. 2022. Molecules. 27: PMID: 35630719
- Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection. | Liu, L. and Nahata, MC. 2023. Ann Pharmacother. 10600280221149708. PMID: 36688309
- Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. | Goldman, RC., et al. 1994. Antimicrob Agents Chemother. 38: 1496-500. PMID: 7979278
Inhibitor of:
2610528E23Rik, Ajuba, Bacillus anthracis spore antigen, Bordetella pertussis, Borrelia burgdorferi Osp A, Chlamydia LPS, cryptdin 22, Cyclosporin A, CYP2B13, CYP2B19, CYP2B23, CYP3A1, Cyp3a11, Cyp3a13, Cyp3a18, Cyp3a25, CYP3A4, CYP3A5, CYP3A7-CYP3AP1, cytochrome b5 type B, ISX, Legionella pneumophila LPS, MRP-63, Mycobacterium avium, Ribosomal Protein L28, UGT2A3, and VacA.Activator of:
CagA, IL-1ra, and VCC-1.Substrate of:
CYP3A4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Clarithromycin, 100 mg | sc-205634 | 100 mg | $77.00 | |||
Clarithromycin, 250 mg | sc-205634A | 250 mg | $122.00 |